Answers are grounded in this paper and cite their sources.
Intermittent fasting (IF) has emerged as a potential adjunctive strategy in cancer prevention, mitigation, and treatment. This narrative review synthesizes existing literature to explore the relationship between IF and cancer across 3 dimensions: prevention, mitigation, and treatment. We examine the underlying mechanisms by which IF may reduce cancer risk, including its effects on insulin-like growth factor 1 suppression, autophagy induction, and chronic inflammation reduction. Furthermore, we discuss IF’s potential to enhance the efficacy of conventional cancer therapies by sensitizing cancer cells, promoting apoptosis, and reducing treatment-related side effects. While promising, the evidence is still limited, and further research is required to elucidate the long-term impact and optimal implementation of IF in cancer care. This review aims to provide health care professionals and patients with a comprehensive understanding of the potential benefits and risks associated with IF as a complementary approach in the oncology setting.
No takes yet. Share an insight, caveat, or question.
Faris et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: